Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Share this post

(Reuters) – Recro Pharma’s shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker’s non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply